iRhythm
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
The iRhythm class action lawsuit accuses the company of making false and misleading statements or failing to disclose non-compliance with FDA marketing regulations and not reporting adverse events as required, all while promoting its heart monitoring devices for unapproved uses. The lawsuit outlines a series of events where iRhythm revised its revenue guidance downwards and issued a Customer Advisory Notice due to concerns raised by the FDA, leading to a drop in its stock price. Additionally, the company faced scrutiny from the FDA and the U.S. Department of Justice, leading to further stock price declines after the disclosure of a subpoena and a warning letter concerning regulatory non-conformities and quality system requirements related to its Zio AT System.
